
Rethinking HCC Surveillance and Treatment Amid a Shifting Risk Landscape
“This is the closest we have been to biomarkers replacing ultrasound,” said Amit G. Singal, MD, MS, FAASLD.
Hepatocellular carcinoma (HCC) surveillance is limited by both the sensitivity of ultrasound and its underuse in routine practice, even as the population at risk shifts toward patients with metabolic dysfunction–associated steatotic liver disease (MASLD).
CancerNetwork® spoke with Amit G. Singal, MD, MS, FAASLD, chief of hepatology and medical director of the Liver Tumor Program at UT Southwestern Medical Center, about who should undergo HCC surveillance, emerging alternatives to ultrasound, and how treatment of the disease is evolving.
Singal began by outlining which patients without cirrhosis may benefit from surveillance and when clinicians should move beyond ultrasound. He then discussed abbreviated MRI and blood-based biomarker panels, including emerging DNA methylation tests, before reviewing interventions designed to improve surveillance adherence. He concluded by describing trends in stage at diagnosis and treatment, the role of multidisciplinary care and immunotherapy-based combination strategies, and BEACON-HCC, a new North American treatment allocation framework.
In addition to his role at UT Southwestern Medical Center, Singal is chief medical officer of Curve Biosciences.
CancerNetwork: How should clinicians decide which patients without cirrhosis need HCC surveillance, and what should they do when ultrasound fails?
Singal: When we think through the at-risk population for HCC surveillance, the standard populations include those with cirrhosis from any etiology, as well as high-risk subgroups with chronic hepatitis B. The high-risk subgroups with chronic hepatitis B can include those defined by demographic variables such as age and sex, but increasingly, we are using clinical risk scores like PAGE-B to define some of these subgroups.
With a shifting epidemiology, we have seen an increasing proportion of patients with MASLD present with HCC in the absence of cirrhosis. Large studies, including systematic reviews and meta-analyses, have suggested that up to one-quarter or even one-third of patients with MASLD-related HCC develop it without cirrhosis. However, the annual incidence of HCC in noncirrhotic MASLD is exceedingly low, and HCC surveillance is not cost-effective when applied to all patients with noncirrhotic MASLD.
More recently, a couple of studies have shown that patients with MASLD and advanced fibrosis have an annual incidence exceeding 0.2% per year, which is our cost-effectiveness threshold for HCC surveillance in noncirrhotic liver disease. The data are converging that this may be a subgroup in whom HCC surveillance could be cost-effective. We need better data to confirm this in broader populations, and it is not yet incorporated in guidelines or considered standard of care. However, if you ask me where the field is going, I think that is where it is going in terms of future recommendations.
The second part of this is what to do when ultrasound fails, whether in patients with cirrhosis or in those with noncirrhotic liver disease. The American Association for the Study of Liver Diseases [AASLD] guidelines recommend considering a screening CT or MRI in patients with ultrasound failure, which is typically defined as poor visualization.1 Part of ultrasound interpretation is not just the presence or absence of liver masses but also an assessment of visualization, which should be graded using the ultrasound visualization score. That score goes from A to C, like grade school, with A being the best and C being the worst. Sensitivity parallels those scores: it is preserved with visualization score A, slightly depressed with score B, and severely depressed with score C, falling all the way to the high 20s [percent]. That is why the AASLD recommends alternative imaging, either a multiphasic CT or a contrast-enhanced MRI, in patients with visualization score C.
Ultrasound performs poorly in some subgroups, including patients with obesity and steatotic liver disease. What alternatives should care teams consider, and how should they choose?
This parallels the prior discussion. Ultrasound can work in some subgroups of patients, but visualization is worse in others, and ultrasound failure is more common in some subgroups, including patients with obesity, those with nonviral etiologies of liver disease such as alcohol-associated liver disease or MASLD, and those with Child-Pugh B or C cirrhosis. Studies have shown that alternative modalities, whether imaging-based or blood-based, have preserved test performance in these subgroups.
Current alternatives include a dynamic contrast-enhanced MRI or a multiphasic CT in patients who are prone to ultrasound failure. Several studies have shown that abbreviated MRI, a short MRI in which in-scanner time is decreased from 45 minutes to 15 minutes by selecting certain sequences, has preserved sensitivity compared with a full diagnostic MRI. Several studies have also evaluated blood-based biomarker panels for early-stage HCC detection.
The biomarker panels furthest along in validation are protein-based, often combined with demographics like sex and age. The most validated and widely available combine sex, age, alpha-fetoprotein [AFP], and des-gamma-carboxy prothrombin [DCP], with or without a third biomarker, lens culinaris agglutinin–reactive AFP [AFP-L3]. These are now commercially available as the GALAD, GAAD, and ASAP panels. Those 3 panels have sensitivity estimates in the mid-60s [percent] and specificity in the 70s to low 80s [percent]. They appear promising and are being evaluated in cohort studies to see how they compare with ultrasound.
There have also been large studies of methylated DNA panels. Two have undergone prospective cross-sectional assessments showing very high sensitivity, including for very early-stage disease, superior to that of ultrasound and numerically higher than that of ultrasound plus AFP. Those cross-sectional studies show high test performance, although we need longitudinal cohort studies to determine clinical utility and to answer questions such as what to do with false-positive results.
What have plasma DNA methylation biomarker panels shown for detecting early-stage HCC, and how close are they to clinical use?
Several blood-based methylated DNA panels have been evaluated for early-stage HCC detection. We have seen one from Helio Genomics and another from Exact Sciences, and most recently, at The Liver Meeting 2026, we saw data from Curve Biosciences.
The methylation panels from Exact Sciences and Helio Genomics have undergone prospective cross-sectional evaluation. Both studies showed higher sensitivity than ultrasound, numerically higher sensitivity than ultrasound plus AFP, and specificity estimates in the low 80s [percent]. The performance looks promising, although we need prospective longitudinal validation of both panels before widespread adoption into clinical practice.
The Curve Biosciences panel was evaluated in a large case-control study. It showed high sensitivity, greater than 80%, for early-stage detection and, most promisingly, sensitivity greater than 70% for very early-stage detection, meaning lesions of 1 to 2 cm, with a specificity of around 81% to 82%.2 Once again, that is very promising performance in a case-control study, most notably the high sensitivity for very early-stage detection. This panel also needs further validation in cohort studies, and that testing is ongoing.
Biomarker panels have made tremendous advances compared with a few years ago. I think we are getting close to seeing these sufficiently validated for consideration in clinical practice, but we need to see cohort evaluations before we fully understand their clinical utility and their role in HCC surveillance. This is the closest we have been to biomarkers replacing ultrasound, and that is the most exciting aspect. Biomarkers have long played a complementary role to ultrasound; right now, we do ultrasound plus AFP. Until recently, we have not had biomarkers with sufficient sensitivity that we could envision a world of biomarker-only surveillance, and that is quite exciting.
What interventions have been evaluated to increase HCC surveillance adherence?
HCC surveillance is limited not only by the sensitivity of ultrasound plus AFP for early-stage detection, with systematic reviews and meta-analyses showing a pooled sensitivity of around 63%, but also by widespread underuse in practice. Several studies have shown that only 1 in 4 patients who develop HCC completed surveillance in the year before their diagnosis. This relates to a combination of patient- and provider-reported barriers. Providers report barriers like limited time in clinic and competing demands, which make it difficult to order and coordinate a separate radiology visit for the ultrasound. Patients report barriers like transportation and uncertainty about where to get the ultrasound done, which relate directly to surveillance being done at a radiology appointment separate from their clinic visit.
Several interventions have been evaluated, including patient education, provider education, and recall systems through radiology. We have evaluated a mailed outreach program in which you identify patients in the health system, mail them a letter saying that they are due for HCC surveillance, and invite them to complete it. All of those interventions, whether relatively simple or more comprehensive and intensive, have increased HCC surveillance, particularly when evaluated over short periods. However, when you evaluate this over repeated intervals, particularly over a multiyear period, the proportion of patients who receive consistent semiannual surveillance still tends to be very low. That speaks to the difficulty of getting repeat imaging appointments separate from a clinic visit.
When it comes to which interventions can best address underuse of HCC surveillance, this is one advantage of blood-based biomarkers, because they can be done at the same time as your clinic visit when you are getting your other blood work. Blood-based biomarkers have the potential not only to increase sensitivity for early-stage detection, as we have seen in some of these recent studies, but also to increase adherence, and this has the best potential to increase overall effectiveness.
How have HCC stage at diagnosis, treatment patterns, and survival changed across treatment eras?
When we look at trends in HCC epidemiology, a few things become very clear. The most evident is a change in the underlying etiologic factors. We have seen a decreasing proportion of patients with HCC related to viral hepatitis, particularly active hepatitis C, and increases in the proportion related to alcohol-associated liver disease and MASLD.
We saw improvements in HCC surveillance utilization over time, particularly from the 2000s to the late 2010s, along with improvements in early detection and receipt of curative therapy. Unfortunately, those gains were largely mitigated during the COVID-19 pandemic. Patients became less engaged with their health systems, screening utilization went down across multiple cancer types, and the same was true for HCC. Many of those gains were wiped out and have not fully recovered. In the 2020s, we have largely returned to a middle ground, similar to where we were before the pandemic, and we are no longer seeing that upward trajectory. At this time, a minority of patients undergo HCC surveillance before their diagnosis, and a minority are found at an early stage, which means only a small proportion are eligible for curative therapies.
The positive is that our treatment regimens have changed over time and our understanding of tumor biology has evolved, which allows us to consider strategies like conversion therapy to resection and downstaging to liver transplantation. Some patients found beyond an early stage can be treated aggressively and thereby become eligible for curative interventions. These strategies are always important to consider and implement when possible.
One of the best predictors of receiving those aggressive interventions is multidisciplinary care. That can be a co-located clinic, where multiple specialties see patients in a single clinic, which we regard as the most patient-friendly approach and which we have implemented at UT Southwestern. Many centers also offer multidisciplinary tumor boards, where multiple disciplines review the imaging and consider which treatment may be best for each patient. There are no comparative data for co-located clinics vs multidisciplinary tumor boards, so I cannot definitively say that one is better than the other. However, several studies consistently show that patients who receive multidisciplinary care do much better than patients who see a single specialty without multidisciplinary assessment, with marked increases in curative therapy, marked improvements in survival, and increases in patient satisfaction. Multidisciplinary evaluation should be regarded as the standard of care for any patient newly diagnosed with HCC.
As immunotherapy moves from advanced disease to patients eligible for embolization, how should clinicians coordinate treatment decisions?
In contrast to where treatment stood 5 years ago, when one therapy was given at a time, we are seeing more and more data for either sequential therapy, in which one therapy is given right before another, or combination therapy. Most notably, we have seen increasing data for neoadjuvant therapy, meaning receipt of immunotherapy before resection, which has shown signals of improved recurrence-free survival. We have also seen data showing that combining immunotherapy with embolic therapy improves progression-free survival.
These interventions should be considered when a patient presents with HCC, and they are often best considered in a multidisciplinary setting, where multiple disciplines can weigh the potential for different therapies as well as the intersection of those therapies. Patients should be considered for these therapies, whether through clinical care or a clinical trial, and the data are promising for improving patient outcomes.
Whenever one considers these therapies, it must be done in the context of the patient’s underlying liver disease. More than 90% of patients who develop liver cancer do so in the setting of chronic liver disease, and any therapy we give can interact with that chronic liver disease. That is another factor to consider when planning therapy and monitoring patients on therapy.
Is there anything else about the evolving HCC treatment paradigm that you would like to highlight?
Treatment paradigms have evolved over time. Simplistically, in the past, there was the Barcelona Clinic Liver Cancer staging system, which outlined a therapy for each stage. However, treatment decisions have become increasingly complex, whether because multiple treatment options are available for a single patient or because combination therapies are possible. We recently codified this into a new treatment allocation system tailored to patients seen in North America: BEACON-HCC, published in Hepatology.3 This treatment allocation system was derived from a multidisciplinary group of experts and validated through multiple cases with an external group of experts, where we showed that it had high concordance with expert recommendations. It starts to give clinicians and patients a starting point for which treatment options may be available based on their individual tumor burden.
References
- Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922-1965. doi:10.1097/HEP.0000000000000466
- Curve Biosciences unveils transformative results for liver disease monitoring with its Whole-Body Blood Test. News release. Curve Biosciences. October 5, 2026. Accessed November 20, 2026. https://tinyurl.com/bdd2rwfn
- Singal AG, Agopian VG, Dawson LA, et al; HCC-Live Steering Committee. BEACON-HCC: best evidence and North American consensus on treatment allocation for hepatocellular carcinoma. Hepatology. Published online August 7, 2026. doi:10.1097/HEP.0000000000001834
Related to this article








